Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
August 08, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock
July 29, 2022 17:27 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena, Inc. Announces Registered Direct Offering of Preferred Stock
July 29, 2022 08:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
July 28, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK demonstrated statistically significant reduced impact on neurocognitive functioning vs IV morphine on primary endpoint Successfully negotiated OLINVYK contract with a large group purchasing...
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care
June 14, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Participate at the JMP Securities Life Sciences Conference
June 10, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 16:05 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports First Quarter 2022 Results and Provides Business Update
May 11, 2022 07:00 ET
|
Trevena, Inc.
OLINVYK refocused commercial strategy initiated mid-Q1 OLINVYK respiratory physiology study demonstrated statistically significant reduced impact on respiratory function compared to IV morphine,...
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
May 09, 2022 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...